Andrew is an experienced business and supply chain leader with passion for innovation, strategy, social impact and change leadership. He is currently CEO at Jamila Therapeutics.
Prior to Jamila, Andrew founded the 3PG Group and PharmaStockUSA, and has also worked for Optel Group, Novartis, Pfizer, Teva and GSK in various roles where he gained multi-national experience in strategy, supply chain, innovation and sustainability in the life science industry.
Andrew has a Bachelors of Science degree from Michigan State University in Material Science and Technology. Andrew currently lives with his wife and two children in Switzerland.